and 75 per cent of subjects at any one follow up visit. There were 19 withdrawals from the treatment group, 10 of which were the result of side effects. There were 5 withdrawals from the control group. According to the original intention to treat, there were 18 deaths at 2 years in the treatment group and 14 deaths in the control group. There was no reduction in the incidence of instantaneous or sudden deaths. Deaths on treatment were not associated with a low phenytoin plasma level. Phenytoin treatment showed no beneficial effects on mortality and was associated with a high incidence of side effects.
Several trials of the effects of long-term antiarrhythmic therapy in survivors of acute myocardial infarction have been reported (Amsterdam et al., 1968; Collaborative Group, 1971; Reynolds and Whitlock, 1972; Kosowsky et al., 1973; Ahimark et al., 1974; Wilhelmsson et al., 1974; Multicentre International Study, 1975) . One collaborative group used phenytoin as an antiarrhythmic agent and made a post hoc observation that patients who had plasma levels of phenytoin above 10 [kg/ml (equivalent to 40 ,umol/l) had a lower mortality in the first year after myocardial infarction than patients with blood levels below this level (Collaborative Group, 1971 ). This observation prompted this prospective study to determine whether long-term therapy with phenytoin, given in doses to maintain blood levels above 40 ,umol/l, would reduce the mortality of patients who suffered acute myocardial infarction.
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Received for publication 13 February 1978 Subjects and methods Between December 1972 and April 1974 505 consecutive patients were admitted to CCU, of whom 220 were diagnosed as having a definite myocardial infarction (World Health Organization, 1971) . Seventy of these patients were excluded from the trial because of one or more of the following: age 70 years or more, chronic diseases involving other systems, mental illness, language difficulties, chronic alcoholism, or additional unrelated heart disease. One hundred and fifty patients were, therefore, recruited to the study. Before randomisation, patients were grouped according to the presence or absence of mechanical and/or electrical complications identified in the CCU (Wilhelmsson Electrical The trial was conducted in an open manner: placebo was not given to the control group. Treatment was started before discharge from the CCU. Patients randomised to the treatment group received phenytoin (Dilantin-Parke Davis) in a dosage schedule of 1 g orally over 20 minutes on the first day, 500 mg as a single dose on the second day, and 400 mg on the third day, and thereafter according to the plasma level. Patients received phenytoin as a single dose during their stay in hospital and as divided doses twice daily after discharge from hospital.
All patients in the study were seen in a special coronary follow-up clinic at 1, 2, 4, 6, 9, 12, 18, and 24 months after recruitment to the study. All patients, irrespective of their randomisation, were treated conventionally during the follow-up period.
Thus beta-receptor antagonists and/or antiarrhythmic drugs were used if indicated. At each scheduled visit to the hospital the plasma level of phenytoin 3 hours after the last oral dose was estimated by a spectrophotometric method which is specific for phenytoin (Wallace, 1968) ; the dosage was adjusted if necessary to maintain the plasma level in the therapeutic range of between 40 and 80 ,umol/l (Bigger et al., 1968) .
Patients who were electively withdrawn from the study were also followed in the same manner.
In the event of death, all efforts were made, including review of official records and interviews with family and observers, to obtain a detailed picture of the circumstances of death. Deaths were classified into one of the following groups: (1) Instantaneous: all deaths which occurred within 3 minutes after the onset of a new major symptom. (2) Sudden, not instantaneous: all deaths which occurred within 24 hours of the onset of a new major symptom, but not within 3 minutes. (3) Not sudden: all deaths which occurred 24 hours or later after the onset of a new major symptom. The results were analysed using x2 contingency tables. A P value of less than 0 05 was considered to be significant.
Results
The matching of treatment and control groups is shown in Table 1 . The two groups were well matched according to the factors used for stratification. They were also well matched with respect to cigarette smoking and the time of recruitment to the study from the onset of acute myocardial infarction. They were not well matched according to the electrocardiographic localisation of infarction. There was a preponderance of anterior infarcts in the control group and an excess of inferior infarcts in the treatment group. Phenytoin plasma levels in the treatment group are shown in Fig. 1 . Though the mean levels at each visit were within the therapeutic range, there was a wide scatter such that the percentage of patients with plasma levels in the therapeutic range at any visit lay between 51 and 75 per cent.
The incidence of toxic phenytoin plasma levels at each scheduled visit and the incidence of symptoms attributable to phenytoin toxicity is shown in Table 3 . Ataxia, diplopia, light headedness, dizziness and nausea were the most common toxic symptoms. There was a lower incidence of toxic levels and an absence of toxic symptoms in the later stages of the trial. Fig. 2 shows the outcome of the trial at two years. According to the original intention to treat, there was a 2-year mortality of 24 per cent in the treatment group compared with 18 per cent in the control group. This difference was not statistically significant.
Further analysis of the mortality data is shown in Table 4 . According to the original intention to treat, there were 4 deaths associated with reinfarction in the treatment group, and none in the control There were 5 non-fatal reinfarctions in the treatment group and an identical number in the control group during the 2-year follow up period. was an excess of anterior infarcts in the control group and an excess of inferior infarcts in the treatment group. This mismatching would be expected to bias the trial in favour of the treatment group as the multicentre practolol study has shown a lower 2-year mortality in patients with inferior infarctions (Multicentre International Study, 1975) . However the multicentre practolol study also shows that treatment was only effective in anterior infarctions. If this is true for phenytoin therapy also, it would offset the trend for a better outcome for the treatment group in our trial. In the control group more patients were receiving digitalis and there was a higher incidence of clinical heart failure, thus again the trial would tend to favour the treatment group. Despite this bias, longterm treatment with phenytoin failed to show any beneficial effect on 2-year mortality, or any reduction in the incidence of instantaneous or sudden death. Though only a little more than half of the treatment group patients had therapeutic plasma levels of phenytoin at any one time, it is important to note that the last measured plasma levels were therapeutic in the majority of patients who died while on phenytoin treatment.
Patients with both electrical and mechanical complications after infarction have a worse longterm prognosis than patients with only one or neither of these complications (Wilhelmsson et al., 1974) . Even in this high risk group, however, there was no reduction in total mortality with phenytoin therapy; there was a reduction in numbers of instantaneous deaths, but the number of patients in the group were too small for this difference to be significant. This group, however, may be a useful one in which to study antiarrhythmic drugs in future trials. Any beneficial effects should be more distinct in this high risk group compared with the full range of patients.
A major aim of this study was to maintain therapeutic phenytoin plasma levels consistently. Despite our vigorous attempts to attain this ideal, at best only three-quarters of the patients had therapeutic phenytoin levels at any visit, and at worst, only half. There is a wide intersubject variation in phenytoin metabolism as shown by the wide variety of biological half-lives previously reported (7 to 42 hours) (Arnold and Gerber, 1970) . Further, it appears that phenytoin metabolism in an individual exhibits enzyme saturatable characteristics, and disproportionate changes in plasma levels may, therefore, occur with small changes in dose when the metabolic enzyme systems become saturated (Perrier et al., 1976) . Though efforts were made to obtain a high degree of patient compliance, there was no satisfactory measure to assess our success in this respect other than to determine whether phenytoin had been taken or not. Our difficulties with controlling plasma levels of treatment have significant connotations for future longterm antiarrhythmic trials. Unless an antiarrhythmic drug has predictable and uniform metabolism, a high degree of plasma level control will be difficult to achieve. If the variations are such that frequent changes in dose are required, it will be difficult to conduct a satisfactory double-blind study.
There was a high withdrawal rate in this study from the treatment group, of the order of that seen in the practolol study and some of the earlier anticoagulant studies. Idiosyncratic phenomena, mainly skin rashes, were the usual cause of withdrawal. Phenytoin toxic symptoms usually responded to reduction in dose of the drug. The incidence of serious side effects was so high (14%) that use of phenytoin as a prophylactic antiarrhythmic agent is contraindicated in the broad range of patients.
